Ryan Scott

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages OncLive's social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: rscott@onclive.com

Articles

Selinexor Receives Approval in South Korea for Multiple Myeloma

October 18th 2024

The South Korean Ministry of Food and Drug Safety approved selinexor plus bortezomib and dexamethasone for pretreated patients with multiple myeloma.

Cabozantinib Plus Atezolizumab Fails to Improve OS Over Subsequent Novel Hormonal Therapy in mCRPC

October 17th 2024

Cabozantinib plus atezolizumab did not produce superior OS outcomes vs a second novel hormonal therapy in metastatic castration-resistant prostate cancer.

Dr Scandura on the SENTRY-2 Trial of Single-Agent Selinexor in JAK Inhibitor–Naive Myelofibrosis

October 16th 2024

Joseph M. Scandura, MD, PhD, discusses the phase 2 SENTRY-2 study evaluating single-agent selinexor in JAK inhibitor–naive myelofibrosis.

Dr Klisovic on a Case Discussion of Momelotinib in Myelofibrosis With Anemia

October 16th 2024

Rebecca Klisovic, MD, discusses 3 case studies about patients with myelofibrosis.

Prospective Trials Could Refine Potential Roles for Radiation in Advanced RCC

October 15th 2024

Chad Tang, MD, discusses how radiation could play a role in advanced renal cell carcinoma.

Dr Weinberg on the Prognostic Use of ctDNA Testing in Resected CRC

October 14th 2024

Benjamin Adam Weinberg, MD, discusses the ability of ctDNA-based MRD detection to predict the benefit of adjuvant chemotherapy in resected CRC.

EU Approval Sought for Darolutamide Plus ADT for mHSPC

October 14th 2024

The EMA has received a submission seeking the approval of darolutamide in combination with ADT in metastatic hormone-sensitive prostate cancer.

Sunvozertinib Receives Breakthrough Therapy Designation for Treatment-Naive EGFR Exon 20+ NSCLC in China

October 14th 2024

China’s CDE has granted breakthrough therapy designation to first-line sunvozertinib for EGFR exon 20 insertion mutation–positive NSCLC.

Meta-Analysis Shows Efficacy, Safety of CAR T-Cell Therapy in R/R Mantle Cell Lymphoma

October 14th 2024

CAR T-cell therapy demonstrated efficacy and manageable safety in mantle cell lymphoma in a systematic review of prospective and real-world studies.

Fixed-Duration Ibrutinib/Venetoclax Elicits Meaningful Survival Benefit in High-Risk CLL/SLL

October 12th 2024

Fixed-duration ibrutinib plus venetoclax generated meaningful survival benefits and durable responses in high-risk subgroups of patients with CLL/SLL.

FDA Approves Single-Dose, Intravenous Paclitaxel Biosimilar for Breast Cancer

October 11th 2024

A single-dose formulation of paclitaxel for injectable suspension has been launched in the United States for metastatic breast cancer.

EU Green Lights CLDN18 RxDx Assay As Companion Diagnostic for Zolbetuximab in Gastric Cancer

October 11th 2024

CE certification was granted to the VENTANA CDLN18 RxDx assay for the assessment of CLDN18 protein expression in gastric or GEJ adenocarcinoma in Europe.

NMPA Grants Marketing Approval to NGS-Based Companion Diagnostic for Sunvozertinib in EGFR Exon 20+ NSCLC

October 11th 2024

A next generation sequencing–based companion diagnostic has received marketing approval in China for sunvozertinib in EGFR exon 20–positive NSCLC.

Shining a Light on the Importance of Prevention Strategies During Breast Cancer Awareness Month

October 10th 2024

Sunil Adige, MD, discusses how breast cancer awareness efforts can enable earlier detection, better disease management, and improved patient outcomes.

Exploring Facets of Both the SCLC and NSCLC Therapeutic Landscapes

October 9th 2024

Eric Kumar Singhi, MD, discusses the current therapeutic landscape and unmet needs in small cell and non–small cell lung cancer.

Emavusertib Plus Ibrutinib Is Under Investigation in the TakeAim Trial in PCNSL

October 7th 2024

Grzegorz S. Nowakowski, MD, discusses the methods and objectives of the part B expansion portion of the TakeAim Lymphoma study in patients with PCNSL.

Novel Anti-Estrogen Therapies Are Poised to Expand Treatment Options in Advanced ER+ Breast Cancer

October 4th 2024

Seth Wander, MD, PhD on novel anti-estrogen therapies that could expand treatment options in estrogen receptor–positive advanced breast cancer.

Emavusertib-Focused Research Is Poised to Expand the PCNSL Treatment Paradigm

October 4th 2024

Grzegorz S. Nowakowski, MD, discusses the unique mechanism of action of emavusertib and highlights the phase 1/2 TakeAim Lymphoma trial in PCNSL.

Real-World Analysis Shows High, Durable Transfusion Independence Rates With Luspatercept in Lower-Risk MDS

October 3rd 2024

Luspatercept generated high rates of durable transfusion independence for patients with lower-risk myelodysplastic syndrome in a real-world analysis.

Uncovering and Addressing Unmet Needs in Pediatric Cancer Care

October 2nd 2024

Saro H. Armenian, DO, MPH, discusses ongoing research that aims to enhance the quality of care for childhood cancer survivors.

NEXT PAGE
PREVIOUS PAGE